Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Vitroscope logo — Enabling breakthrough cell culture models by leveraging perf...

Vitroscope

Enabling breakthrough cell culture models by leveraging perfusion & automation.

Founded 2019 Norway Norway 6 employees Seed Total: $530.00K Biotechnology, Life Sciences

General Information

Company Name Vitroscope
Founded Year 2019
Location Norway Norway
Employees 6
Industries Biotechnology, Life Sciences
Funding Stage Seed
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Usage Based, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Vitroscope. To contact Vitroscope, visit vitroscope.no.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vitroscope compare?

A PDF of Vitroscope and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vitroscope soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vitroscope

Vitroscope, founded in 2019 and headquartered in Norway, is pioneering advancements in the Biotechnology and Life Sciences industries. The company is known for its slogan: "Enabling breakthrough cell culture models by leveraging perfusion & automation."

With a transformative platform, Vitroscope facilitates the study of immune activity, drug effects, and disease mechanisms by maintaining the native microenvironment of living human tissues. Their integrated system supports various applications, including tissue, 2D, mechanobiology, organoids, and 3D bioprints, while ensuring compatibility with both up- and downstream screenings.

In terms of funding, Vitroscope last received a seed investment on 01 December 2021 from StartupLab. This strategic financial backing positions the company to further innovate and expand its reach in the field of human tissue study.

Business keywords: Cell Culture Models, Perfusion Technology, Vascularised Organoids, Microenvironment Control, Drug Effects Study, Immune Activity Study, Disease Mechanism Study, Mechanobiology, Organoid Technology, Ex Vivo Tissue Research, Biomedical Engineering, 3D Bioprints, Live Cell Analysis

Services & Products

Controlled Flow for Vascularised Organoids
Preservation of Native Microenvironment
Ex Vivo Tissue Culture Solutions
Dynamic Culture Systems
Real-Time Supernatant Monitoring
Custom Experiment Protocols

Target Customers

Research Institutions Biotechnology Companies Pharmaceutical Companies Academic Researchers Medical Researchers

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Undisclosed 1
StartupLab
StartupLab
01 Dec 2021
Grant kr30.00K 1
Innovation Norway
Innovation Norway
01 Nov 2020
Grant kr500.00K 1
Innovation Norway
Innovation Norway
01 Oct 2019

Latest News

View All
Nordic early-stage startups to watch - according to investors — Sifted
Nordic early-stage startups to watch - according to investors
Sifted Jun 07, 2024

Vitroscope Alternatives & Competitors

View All Alternatives
Vitroscope vs
Emulate, Inc.
Emulate, Inc. United States

Our Organ-on-a-Chip technology provides a high-fidelity window into the inner workings of human biol...

Series F
71 employees
Biotechnology, Health Care
Vitroscope vs
Lena Biosciences
Lena Biosciences United States

3D Cell Culture & Perfused-Organ-Panel MPS Technology

Grant
4 employees
Biotechnology, Life Sciences
Vitroscope vs
Basilard BioTech, Inc.
Basilard BioTech, Inc. United States

Nanomechanical Gene Delivery to Transform the Engineering of Cell Based Therapies

Seed
5 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Vitroscope

Enabling breakthrough cell culture models by leveraging perfusion & automation.
Vitroscope was founded in 2019.
Vitroscope is headquartered in Norway.
Vitroscope operates in Biotechnology and Life Sciences. Its work centres on Cell Culture Models, Perfusion Technology, Vascularised Organoids and Microenvironment Control. Its customers include Research Institutions, Biotechnology Companies and Pharmaceutical Companies.
Vitroscope has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Usage Based and Service Fee.
Vitroscope has approximately 6 employees.
Vitroscope has completed 3 funding rounds, raising a total of $530.00K. The latest funding stage is Seed.
Vitroscope offers: Controlled Flow for Vascularised Organoids, Preservation of Native Microenvironment, Ex Vivo Tissue Culture Solutions, Dynamic Culture Systems, Real-Time Supernatant Monitoring, Custom Experiment Protocols.
Top alternatives and competitors to Vitroscope include Emulate, Inc., Lena Biosciences, Basilard BioTech, Inc., InvivoSciences® Inc., ATCG India. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vitroscope and Emulate, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vitroscope, https://bouncewatch.com/company/vitroscope, updated 2 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout